Company: Puma Biotechnology Inc.
Job title: Sr. Director, Translational Medicine & Diagnostics
Lisa Eli has more than 15 years of experience in Oncology Precision Medicine, specifically in biomarker and companion diagnostic development for breast cancer and other solid tumors. She currently serves as Senior Director of Translational Medicine and Diagnostics at Puma Biotechnology, where she focuses on preclinical and clinical development for neratinib, a HER2-specific, irreversible tyrosine kinase inhibitor that targets HER2 mutations and amplifications. Lisa earned her PhD in Biochemistry at Stanford University and completed her post-doctoral training at UCSF.
Live Presenter Q&A 5:00 pm
day: Day One
Targeting Somatic HER2 Mutations Across Multiple Cancers With the Pan-HER Kinase Inhibitor, Neratinib: Lessons From the Phase 2 SUMMIT ‘Basket’ Trial 4:20 pm
• Somatic HER2 mutations are oncogenic driver mutations across a broad spectrum of cancers • HER2 mutations are clinically actionable with HER2 directed therapies • Neratinib demonstrates encouraging clinical efficacy either as a single agent or in combination in HER2 mutant breast, cervical, bile duct and lung cancersRead more
day: Day One